New Ways to Make the Undruggable Druggable
PROSION’s platform of cutting-edge chemical building blocks (ProMs) is able to unlock “undruggable” pharmaceutical targets that are linked with various hard-to-treat diseases.
PROSION developed a first-in-class approach to address so far undruggable pharmaceutical targets that are linked with various hard-to-treat diseases through a disruptive platform of chemical building blocks called ProMs.
ProMs can in fact be combined to form the world’s first small molecule drugs for a very abundant class of “undruggables”, namely proline-rich-motif (PRM) binding targets.
These targets are known to play key-roles in a multitude of pathologies, e.g. cancer, diabetes, Alzheimer’s, cardiovascular diseases, immune-meditated disorders, etc.
The potential of the ProM-platform has already been validated in a first POC targeting Ena/VASP, a particularly difficult oncological PRM-binding target.
As a proof-of-concept, PROSION developed highly selective ProM-based inhibitors for Ena/VASP – a particularly difficult drug target that plays a key role in both, breast and pancreatic cancer metastasis – thereby, identifying the currently only reported (and patented) small molecule inhibitor of PRM-recognizing targets.
Our Focus Area
Generating ProM-based compounds for drug development
We are striving to push our own drug compounds through pre-clinical and clinical development. If you are interested in becoming part of this exciting journey, please head to our contact page.
Providing ready-to-use ProMs as lead compounds
We provide access to our ProM-platform, enabling our potential partners to gain an in-depth scientific understanding. If you are interested in working with our ProMs, please head to our contact page.
PROSION attended the Winter Private Company Showcase with Solebury Trout. The event featured presentations, panels, and 1×1 calls with selected private biotech investors and companies.
PROSION attended the virtual management access event to meet with life science investors from January 6-15, 2021.
Designed nanomolar small-molecule inhibitors of Ena/VASP EVH1 interaction impair invasion and extravasation of breast cancer cells